A federal program that has helped hold down standalone Part D premiums is scheduled to stop after next year’s coverage starts. The Centers for Medicare & Medicaid Services describes the Part D Premium Stabilization Demonstration as voluntary, narrowed for 2026 and slated for discontinuation in 2027. Nothing changes for a member’s coverage today; the rule change is a forward-looking one, and the reader-relevant dates arrive with Open Enrollment, which runs October 15 to December 7.
What CMS said about the demonstration
The language comes from the agency’s September 28 landscape release. CMS wrote that “there are encouraging signs that, as expected, the Part D program is returning to normal market conditions following the narrowing of the voluntary Part D Premium Stabilization Demonstration for CY 2026 and its planned discontinuation in 2027.” The release is the primary CMS statement on the schedule, and it is cast as a planned wind-down rather than a sudden cut.
The same CMS release announces that the total average monthly premium for stand-alone drug plans is projected to rise from $35.09 to $36 in 2027, an increase of less than a dollar. That is the 2027 picture with the demonstration narrowed, not a forecast of what premiums will look like in 2028 after it ends.
Elsewhere in the release, CMS reports that the average monthly Part D premium inside Advantage plans is projected to fall from $11.32 to $7, and that 88 percent of non-low-income beneficiaries will have access to a basic Part D plan at $10.30 or less. Those figures describe the 2027 market as it is priced with the demonstration narrowed, and they are the context for the planned end.
What a demonstration is, and why it matters to a premium
The release does not spell out the demonstration’s mechanics, and this report does not guess at them. What CMS does say is that it is voluntary for plan sponsors, that it was narrowed for 2026, and that the Part D program is returning to normal market conditions as it winds down. The reasonable reading, stated as an inference and not as CMS’s words, is that plan premiums will increasingly reflect what plans bid on their own.
Two other 2027 numbers frame the exercise. CMS set the national average monthly bid amount at $296.05 and the base beneficiary premium at $41.33 in a July fact sheet, and every standalone plan’s premium is built from its own bid relative to that base.
What the benefit redesign keeps in place
The end of one stabilizing program sits beside rules that stay. A CMS fact sheet on the contract-year 2027 final rule, dated April 2, 2026, describes the codification of Inflation Reduction Act changes in Part D: eliminating the coverage gap phase, establishing a reduced annual out-of-pocket threshold, and removing cost sharing for enrollees in the catastrophic phase. Medicare’s costs page still shows the Part D out-of-pocket limit as $2,100 for 2026, and it does not yet show a 2027 limit.
Those protections cap what a member pays for covered drugs in a year, whatever the plan charges in premium. A premium change therefore moves the fixed cost of having the plan, while the out-of-pocket ceiling bounds the variable cost of using it. The distinction is why the two pieces of 2027 news, a premium average that edges up and a demonstration that is ending, should be read separately.
Nothing to file, and no deadline attached to the rule
No form, application or deadline attaches to the demonstration itself. Members of standalone Part D plans do not enroll in it or lose it by missing a date; the effect shows up in the premium a plan charges. The dates that matter are those of the ordinary fall enrollment period, and any member who wants to compare plans can use the Medicare Plan Finder at medicare.gov, which the CMS release describes as a way to compare health and drug plans on premiums, costs and benefits.
Extra Help members have a separate set of numbers. Medicare’s drug cost help page shows 2027 copays of up to $5.80 for a generic and up to $14.40 for a brand-name drug for those who qualify, so a change in the base premium environment is not the only factor in what a low-income member pays.
Take a hypothetical member whose standalone plan premium moves by the national average change of under a dollar a month: the annual difference is about $11, small beside the cost of a prescription that lands in a higher tier. The note of caution is that the end of a demonstration is not by itself a premium forecast. The primary source says what is planned for 2027, and the premium effects of the full discontinuation will be visible only in later pricing, and CMS’s release does not forecast them.
The Part D premium support scheduled to end in 2027
The voluntary Part D Premium Stabilization Demonstration is slated to end in 2027, and nothing about that requires action today. The practical question for next year’s drug coverage is how plan prices look once the support is gone, and that can be read only from each plan’s own 2027 documents during the fall window.
The 2027 Medicare Open Enrollment Decision Kit supplies the Open Enrollment calendar and a prescription-by-plan comparison, so a standalone drug plan can be checked against finalists when the dates arrive.
Line up a standalone drug plan against its finalists before December 7 →
Drafted with AI assistance; the program details and figures were checked against the cited CMS pages.
